Does the lack of survival data with palbociclib in metastatic breast cancer make you lean towards using abemaciclib or ribociclib in various combinations?

While some comparative studies have shown survival differences among CDK4/6i, it is unclear how these differences will play out when CDK4/6i are combined with PI3K/AKT inhibitors. I prefer to evaluate the different combinations individually, paying attention to the efficacy, clinical context where the combination is tested, patient factors, and side effect profile.